Our Solutions

About Us

J

Dr John Mascarenhas, MD

Medical professional dedicated to sharing knowledge and insights through educational videos.

Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

Recognizing HU Resistance: When to Switch

John Mascarenhas, MD

Hematologic Malignancies

Dr. John Mascarenhas discusses the impact of pacritinib to transfusion burden seen in the PERSIST-2 trial (video 3/3).

Dr. John Mascarenhas discusses the impact of pacritinib to transfusion burden seen in the PERSIST-2 trial (video 3/3).

PERSIST2-Transfusion Burden

John Mascarenhas, M.D.

Hematologic Malignancies

Dr. John Mascarenhas discusses recent updates to the NCCN guidelines for myelofibrosis (video 2/3).

Dr. John Mascarenhas discusses recent updates to the NCCN guidelines for myelofibrosis (video 2/3).

PERSIST2-NCCN

John Mascarenhas, M.D.

Hematologic Malignancies

Dr. John Mascarenhas discusses the efficacy of low dose ruxolitinib vs pacritinib in myelofibrosis based on a retrospective analysis of PERSIST-2 (video 1/3).

Dr. John Mascarenhas discusses the efficacy of low dose ruxolitinib vs pacritinib in myelofibrosis based on a retrospective analysis of PERSIST-2 (video 1/3).

PERSIST2-Rux vs pac

John Mascarenhas, M.D.

Hematologic Malignancies

ideology-health

Terms of Service

IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.